Harvard Bioscience Inc (HBIO): Next-Year EPS Estimate 269.74%
As of 2026-08-25, Harvard Bioscience Inc (HBIO) has a next-year EPS growth estimate of 269.74%. Featured in our EPS revision report on 2026-08-20.
On 2026-08-12, analyst consensus for HBIO's next-year EPS growth shifted from 169.34% to 269.74% — a positive change of 100.40 percentage points. The revised estimate has been sustained across 12 subsequent trading sessions. Current-year growth is projected at -90.00%.
What's Driving This
The primary driver is a large upward revision to Harvard Bioscience’s next-year EPS growth estimate, raised from 169.34% to 269.74% on 2026-08-12. This upgrade follows the company’s Q2 earnings beat and its decision to raise 2026 revenue guidance, as highlighted in recent headlines. The estimate has continued climbing for two consecutive trading sessions, adding roughly 107 percentage points since the initial revision, indicating sustained positive momentum.
Generated 2026-08-25 from news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- EPS growth next year
- 269.74%
- EPS growth this year
- -90.00%
- EPS next quarter (est)
- -$0.17
- Last price
- $7.58
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 269.74% | -90.00% | -$0.17 | $7.58 |
| 2026-08-24 | 269.74% | -90.00% | -$0.17 | $7.55 |
| 2026-08-23 | 269.74% | -90.00% | -$0.17 | $7.48 |
| 2026-08-21 | 269.74% | -90.00% | -$0.17 | $7.48 |
| 2026-08-20 | 269.74% | -90.00% | -$0.17 | $7.55 |
| 2026-08-19 | 269.74% | -90.00% | -$0.17 | $7.08 |
| 2026-08-18 | 269.74% | -90.00% | -$0.17 | $6.97 |
| 2026-08-17 | 269.74% | -90.00% | -$0.17 | $6.50 |
| 2026-08-16 | 269.74% | -90.00% | -$0.17 | $6.66 |
| 2026-08-14 | 269.74% | -90.00% | -$0.17 | $6.66 |
| 2026-08-13 | 269.74% | -90.00% | -$0.17 | $6.67 |
| 2026-08-12 | 269.74% | -90.00% | -$0.17 | $6.17 |
| 2026-08-11 | 169.34% | -242.50% | -$0.28 | $6.13 |
| 2026-08-10 | 162.86% | -250.00% | -$0.21 | $6.39 |
| 2026-08-09 | 162.86% | -250.00% | -$0.21 | $6.47 |
| 2026-08-07 | 162.86% | -250.00% | -$0.21 | $6.47 |
| 2026-08-06 | 162.86% | -250.00% | -$0.21 | $6.19 |
| 2026-08-05 | 162.86% | -250.00% | -$0.21 | $6.37 |
| 2026-08-04 | 162.86% | -250.00% | -$0.21 | $6.31 |
| 2026-08-03 | 162.86% | -250.00% | -$0.21 | $6.31 |
| 2026-08-02 | 162.86% | -250.00% | -$0.21 | $6.10 |
| 2026-07-31 | 162.86% | -250.00% | -$0.21 | $6.10 |
| 2026-07-30 | 162.86% | -250.00% | -$0.21 | $6.09 |
| 2026-07-29 | 162.86% | -250.00% | -$0.21 | $6.12 |
| 2026-07-28 | 162.86% | -250.00% | -$0.21 | $5.92 |
| 2026-07-27 | 162.86% | -250.00% | -$0.21 | $5.99 |
| 2026-07-26 | 162.86% | -250.00% | -$0.21 | $6.00 |
| 2026-07-24 | 162.86% | -250.00% | -$0.21 | $6.00 |
| 2026-07-23 | 162.86% | -250.00% | -$0.21 | $6.19 |
| 2026-07-22 | 162.86% | -250.00% | -$0.21 | $6.13 |
Reports Featuring HBIO
Recent News
- Harvard Bioscience, Inc. Q2 2026 Earnings Call SummaryMoby
- Harvard Bioscience, Inc. Q2 2026 Earnings Call SummaryMoby
- Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...GuruFocus.com
- Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...GuruFocus.com
- Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidanceInvestorsHub
- Harvard Bioscience: Q2 Earnings SnapshotAssociated Press
- Harvard Bioscience Announces Second Quarter 2026 Financial ResultsGlobeNewswire
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Harvard Bioscience Inc's next-year EPS growth estimate?▾
As of 2026-08-25, Harvard Bioscience Inc (HBIO) has a next-year EPS growth estimate of 269.74%, based on analyst consensus.
When was the latest EPS estimate revision for HBIO?▾
The most recent revision occurred on 2026-08-12, when analysts adjusted the next-year EPS growth estimate from 169.34% to 269.74%.
What sector and industry does Harvard Bioscience Inc belong to?▾
Harvard Bioscience Inc operates in the Healthcare sector, specifically the Medical Instruments & Supplies industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. HBIO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Harvard Bioscience Inc (HBIO) appears here because it was detected by our daily top-EPS-revision-performer screen.